Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2026
Beyond Air, Inc. announced it will report its financial results for the quarter ended September 30, 2026, on November 11, 2026.
Stocks · News reference
8-K filing — Beyond Air, Inc. (XAIR)
Filed: 2026-10-08 AccNo: 0001493152-26-046268 Size: 230 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Beyond Air Affirms FY2027 Sales Guidance of $16.000M-$18.000M vs $16.715M Est
Beyond Air (NASDAQ:XAIR) affirms FY2027 sales outlook from $16.000 million-$18.000 million to $16.000 million-$18.000 million vs $16.715 million estimate.
Beyond Air Reports Q2 Preliminary Revenue Of ~$2.3M, Reiterates FY26 Revenue Range $16M - $18M
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve
Beyond Air New US Patent App #20260284331 Published Today For "METHODS EMPLOYING GASEOUS NITRIC OXIDE FOR INHIBITING TUMOR GROWTH".
https://x.com/US_Patent_Plays/status/2103212175091200022https://ppubs.uspto.gov/pubwebapp/external.html?q=(20260284331).pn
Lake Street Initiates Coverage On Beyond Air with Buy Rating, Announces Price Target of $10
Beyond Air shares are trading higher after the FDA granted the company Breakthrough Device Designation to LungFit GO for the treatment of nontuberculous mycobacterial pulmonary disease